View GHRP-6 Certificate of Analysis
Why Choose GHRP-6 Acetate?
GHRP-6 (Growth Hormone-Releasing Peptide 6) is a synthetic hexapeptide that functions as a potent agonist of the Growth Hormone Secretagogue Receptor (GHS-R), also known as the ghrelin receptor . It is one of the first and most well-characterized members of the GHRP class and remains a gold standard to which other GH secretagogues are related and compared in research . Understanding its distinct origins and mechanisms provides important context for researchers studying the ghrelin-GHSR axis.
The History & Origins
The development of GHRP-6 began in 1977 when Bowers and colleagues published seminal work describing the growth hormone-releasing properties of peptides derived from met-enkephalin that lacked opiate properties . The first compound was a weak GH secretagogue, but it provided a model for designing more potent forms. Through iterative structural modifications—a complex process of trial and error—the hexapeptide GHRP-6 was synthesized .
GHRP-6 is characterized by the inclusion of two D-amino acids in its structure, which confers stability and improved potency . It was the first non-GHRH compound found to act on the anterior pituitary to specifically release GH and is now considered a first-generation peptidyl GH secretagogue . GHRP-6 serves as the pharmacological benchmark for the GH secretagogue receptor, and its development ultimately led to the cloning of the GHS receptor in 1996 by the Merck group, which subsequently enabled the identification of ghrelin as the receptor’s endogenous ligand .
How They Work: Distinct Mechanisms
GHRP-6 operates through a mechanism of action that is distinct from GHRH, making it a unique tool for endocrine and neuroendocrine research.
Ghrelin Receptor (GHS-R1a) Agonist Mechanism
-
Receptor binding — GHRP-6 binds to the growth hormone secretagogue receptor (GHS-R1a), which is primarily expressed in the hypothalamus and pituitary . It inhibits binding of the non-peptide agonist MK-0677 to COS-7 cell membranes expressing human GHS-R type Ia with a Ki of 1.9 nM and binds to the ghrelin receptor with a Kd of 260 nM .
-
Calcium mobilization and IP3 production — Receptor activation stimulates intracellular calcium mobilization (EC50 = 4.5 nM) and inositol phosphate production (EC50 = 0.83 nM) .
-
Signaling pathway — GHRP-6 activates the phospholipase-C pathway, resulting in a rise in inositol triphosphate and intracellular calcium—a pathway distinct from the cAMP-protein kinase A pathway utilized by the GHRH receptor .
Stimulation of Growth Hormone Release
-
Potent GH secretagogue — GHRP-6 is a highly potent peptide that specifically causes the release of GH in all species tested to date, including humans . In rat pituitary cells, 0.03 μg/ml induces release of GH, but not TSH, LH, or FSH .
-
Synergy with GHRH — One of the main properties of GHRP-6 is its ability to act synergistically with GHRH. When both compounds are administered sequentially at saturating doses, they induce a large GH release that is greater than the sum of what each compound would release alone, revealing that they act via different mechanisms .
-
Desensitization — GHRP-6 desensitizes cells to other GHRPs (such as GHRP-2) but does not desensitize cells to GHRH, confirming distinct receptor mechanisms .
Off-Target Effects
-
ACTH and cortisol elevation — Unlike the more selective ipamorelin, GHRP-6 consistently elevates ACTH and cortisol levels, which is important for studies involving stress-response and hypothalamic-pituitary-adrenal (HPA) axis research .
